Argenica Therapeutics (ASX:AGN) said the independent Data Safety Monitoring Board recommended that the phase two clinical trial of neuroprotective peptide drug candidate, ARG-007, in acute ischaemic stroke patients continue with no modification, according to a Thursday filing with the Australian bourse.
The board reviewed the safety data of the first 76 patients dosed in Argenica's phase two trial, which represents a review of 83% of patients in the study.
The board is an independent multidisciplinary committee consisting of an independent chairperson neurologist, two additional independent neurologists, and a biostatistician with relevant clinical trial experience.
Dosing is 86% complete, with 79 patients dosed in the phase two trial, with eight of the 10 activated hospitals having dosed patients, according to the filing. Dosing of all 92 patients is expected to be completed in the second quarter.
The firm's shares rose past 4% in recent trading on Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.